{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:31:08Z","timestamp":1768782668982,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.ahj.2006.05.030","type":"journal-article","created":{"date-parts":[[2006,9,23]],"date-time":"2006-09-23T07:29:02Z","timestamp":1158996542000},"page":"705-712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction"],"prefix":"10.1016","volume":"152","author":[{"given":"Simon","family":"de Denus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martial G.","family":"Bourassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Normand","family":"Racine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Levesque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anique","family":"Ducharme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2006.05.030_bib1","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2006.05.030_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"The SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2006.05.030_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2006.05.030_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000013599","article-title":"Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors","volume":"20","author":"Ahuja","year":"2000","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ahj.2006.05.030_bib5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2006.05.030_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2006.05.030_bib7","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2006.05.030_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0002-9149(90)90842-O","article-title":"Studies of left ventricular dysfunction (SOLVD)\u2014rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction","volume":"66","author":"The SOLVD Investigators","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2006.05.030_bib9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0002-8703(94)90490-1","article-title":"Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction","volume":"128","author":"Kostis","year":"1994","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2006.05.030_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.ahj.2006.05.030_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2006.05.030_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2006.05.030_bib13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2006.05.030_bib14","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","author":"The RALES Investigators","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2006.05.030_bib15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","article-title":"Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases","volume":"110","author":"Schepkens","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2006.05.030_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2006.05.030_bib17","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0002-9149(02)02580-8","article-title":"Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade","volume":"90","author":"Blaustein","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2006.05.030_bib18","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0002-8703(99)70009-8","article-title":"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)","volume":"138","author":"Knight","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2006.05.030_bib19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/pgmj.71.839.551","article-title":"Hyperkalaemia in diabetes: prevalence and associations","volume":"71","author":"Jarman","year":"1995","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ahj.2006.05.030_bib20","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/0002-9343(87)90213-0","article-title":"Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure","volume":"82","author":"Packer","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2006.05.030_bib21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1527-5299.2003.02397.x","article-title":"Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism","volume":"9","author":"Sica","year":"2003","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.ahj.2006.05.030_bib22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0735-1097(98)00297-6","article-title":"Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials","volume":"32","author":"Dries","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2006.05.030_bib23","doi-asserted-by":"crossref","first-page":"14A","DOI":"10.1016\/0735-1097(93)90456-B","article-title":"Natural history and patterns of current practice in heart failure","volume":"22","author":"Bourassa","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2006.05.030_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/01.CIR.84.1.40","article-title":"Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients","volume":"84","author":"Middlekauff","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.05.030_bib25","first-page":"VI102","article-title":"The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies","volume":"87","author":"Carson","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.05.030_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0735-1097(98)00221-6","article-title":"Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm","volume":"32","author":"Pozzoli","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2006.05.030_bib27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00365519309088406","article-title":"The effect of digoxin on the serum potassium concentration","volume":"53","author":"Edner","year":"1993","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.ahj.2006.05.030_bib28","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0008-6363(96)88526-9","article-title":"Digoxin affects potassium homeostasis during exercise in patients with heart failure","volume":"29","author":"Schmidt","year":"1995","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2006.05.030_bib29","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1161\/01.CIR.81.6.1744","article-title":"Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study","volume":"81","author":"Antman","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.05.030_bib30","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0002-8703(96)90365-8","article-title":"Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"131","author":"Kostis","year":"1996","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2006.05.030_bib31","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2006.05.030_bib32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archinte.161.2.165","article-title":"Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival","volume":"161","author":"Massie","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2006.05.030_bib33","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","volume":"46","author":"Hunt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2006.05.030_bib34","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/eurheartj\/ehi204","article-title":"Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology","volume":"26","author":"Swedberg","year":"2005","journal-title":"Eur Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870306005497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870306005497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:29:30Z","timestamp":1757568570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870306005497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0002870306005497"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2006.05.030","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2006.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}